IDEAYA initiates Phase 1 trial for first-in-class dual KAT6/7 inhibitor IDE574
IDEAYA Biosciences (NASDAQ:IDYA) announced today the first-patient-in for its Phase 1 dose-escalation clinical trial of IDE574, a potential first-in-class oral dual inhibitor of KAT6 and KAT7 targeting a broad range of solid tumors.











